Table 2.

Performance of the Panbio COVID-19 Antigen Rapid Test Device by Type of Sample and Site of Care

Variable	TP	FP	TN	FN	PPA (95% CI)	NPA (95% CI)	OPA (95% CI)	Kappa (95% CI)
Type of Sample
NP sample	118	0	709	77	60.5% (53.3–67.4)	100% (99.3–100)	91.5% (89.4–93.2)	0.71 (0.65–0.77)
Nasal sample	59	0	527	73	44.7% (36.1–53.6)	100% (99.1–100)	88.9% (86.2–91.2)	0.56 (0.48–0.65)
Saliva sample	28	0	490	93	23.1% (16.2–31.9)	100% (99–100)	84.8% (81.6–87.6)	0.33 (0.23–0.42)
Site of Care
Primary care	78	0	544	59	56.9% (48.2–65.3)	100% (99.1–100)	91.3% (88.9–93.3)	0.68 (0.60–0.75)
Emergency department	40	0	165	18	69% (55.3–80.1)	100% (97.2–100)	91.9% (87.3–95)	0.77 (0.67–0.87)

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FN, false negative; FP, false positive; NP, nasopharyngeal; NPA, negative percent agreement; OPA, overall predictive agreement; PPA, positive percent agreement; TN, true negative; TP, true positive; y, year.

NOTE: Unless specified, all analyses have been performed in NP samples.